This chapter investigates the underreporting of side effects from clinical trials for statin medications, highlighting biases that affect trial outcomes. A junior doctor's tensions following a controversial article on statins illustrate the challenges faced when questioning established medical beliefs. It also discusses the genetic origins of cholesterol levels, calling for a reevaluation of cholesterol's role in heart disease and the implications of industry influence on medical practice.